Table 1.
Examples of preclinical immunization with self-replicating RNA viruses targeting viral diseases.
Indication | Target/Antigen | Vector | Response | Ref. |
---|---|---|---|---|
Dengue | DV2 | MV | Neutralizing Abs | [37] |
DV1-4 | MV | Protection | [38] | |
Ebola | GP | KUN VLPs | Protection | [39] |
GP | VSV | Protection | [40,41] | |
GP, NP | VEE VLPs | Protection | [42,43] | |
HBV | HBsAg | MV | Humoral Abs | [45] |
MHB | SFV-VLVs | Protection | [46] | |
HIV | Env | SFV VLPs | Humoral response | [47] |
Env | SFV RNA | Antibody response | [48] | |
Env/Gag/Pol | SFVVLPs/RNA | Ag-specific immune response | [49] | |
Env/GagPolNef | SFV DNA | T cell and IgG responses | [50] | |
Influenza | NP | SFV VLPs | Mucosal immune response | [51] |
HA | VEE VLPs | Protection | [52] | |
HA, NP | SFV VLPs | Protection | [53] | |
HA | VEE RNA | Protection | [54] | |
Lassa | Glycoprotein | VSV VLPs | Protection | [55] |
GPC | VEE VLPs | Protection | [56] | |
Lassa | Lassa VLPs | Protection | [57] | |
MERS-CoV | MERS-S | MV | Protection | [58] |
SARS-CoV | SARS-CoV GP | VEE VLPs | Protection | [59] |
MPV | MPV-F | VEE VLPs | Reduced viral load | [60] |
RSV | RSFV-F | SFV-VLPs | Protection | [53] |
RSV-F | VEE VLPs | Reduced viral load | [60] | |
RSV-F | VEE LNPs | Protection | [61] | |
SIV | Gag-pol | KUN VLPs | Protection | [62] |
SIVmacJ5 | SFV VLPs | Cytotoxic T cell response | [63] | |
TBEV | GP | SFV VLPs | Protection | [53] |
VEE | VEE replicon | VEE miRNA | VEE inhibition | [64] |
VEE RdRp | VEE miRNA | VEE inhibition | [65] |
Ag, antigen; DV, Dengue virus envelope protein; GCP, glycoprotein; GP, glycoprotein; HA, hemagglutinin; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; KUN, Kunjin virus; LNPs, lipid nanoparticles; MERS-CoV, Middle East respiratory syndrome coronavirus; MERS-S, Middle East respiratory syndrome spike protein; MHB, HBV middle surface envelope glycoprotein; miRNA, micro RNA; MV, measles virus; NP, nucleoprotein; RdRp, RNA-dependent RNA polymerase; RSV, respiratory syncytial virus; SARS-CoV, severe acute respiratory syndrome corona virus; SFV, Semliki Forest virus; SIV. Simian immunodeficiency virus; TBEV, Tick-borne encephalitis virus; VEE, Venezuelan equine encephalitis virus; VLPs, virus-like particles; VLVs, virus-like vesicles; VSV, vesicular stomatitis virus.